Samsung Bioepis Partners With Nipro to Commercialize Biosimilars in Japan

Trading View
2025.06.10 07:33
portai
I'm PortAI, I can summarize articles.

Samsung Biologics subsidiary Samsung Bioepis signed a licensing and commercialization agreement with Japan's Nipro Corporation to bring several biosimilar candidates, including SB17, a ustekinumab biosimilar, to Japan. Under the agreement, Samsung Bioepis will oversee development, manufacturing, and supply, while NIPRO will handle commercialization in Japan, Samsung Bioepis said in a Monday press release. The partnership aims to expand Samsung Bioepis' presence in Japan and improve access to cost-effective biologic treatments, it said.

Samsung Biologics subsidiary Samsung Bioepis signed a licensing and commercialization agreement with Japan's Nipro Corporation to bring several biosimilar candidates, including SB17, a ustekinumab biosimilar, to Japan.

Under the agreement, Samsung Bioepis will oversee development, manufacturing, and supply, while NIPRO will handle commercialization in Japan, Samsung Bioepis said in a Monday press release.

The partnership aims to expand Samsung Bioepis' presence in Japan and improve access to cost-effective biologic treatments, it said.

Source: Trading View The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.